低剂量喹硫平增加主要心血管不良事件风险:全国性活性对照队列研究
该研究在丹麦2003-2017年纳入60,566名低剂量喹硫平使用者与454,567名Z类药物使用者进行活性对照队列分析,发现低剂量喹硫平与主要心血管不良事件及心血管死亡风险升高相关,女性及≥65岁者风险更高,建议不鼓励超说明书低剂量用于镇静催眠。
要点
- 低剂量喹硫平较Z类药物增加主要心血管不良事件风险(aHR=1.13)。
- 持续用药时风险更高:主要心血管不良事件aHR=1.52,心血管死亡aHR=1.90。
- 女性及≥65岁起始者风险更高,应避免超说明书用于镇静催眠。
核心结论
- 低剂量喹硫平使用与主要心血管不良事件风险增加相关,尤其在女性和老年人中。
研究设计与样本
- 全国性活性对照队列研究,纳入丹麦2003-2017年18-85岁新使用者,排除缺血性卒中、心肌梗死、癌症和严重精神疾病史。
- 比较60,566名低剂量喹硫平使用者与454,567名Z类药物使用者,意向治疗分析随访890,198人年,按治疗分析随访330,334人年。
- 敏感性分析以SSRIs作为替代对照。
主要发现
- 意向治疗分析中,低剂量喹硫平与主要心血管不良事件风险升高相关(aHR=1.13,95%CI:1.02-1.24,p=0.014)。
- 意向治疗分析中,低剂量喹硫平与心血管死亡风险升高相关(aHR=1.26,95%CI:1.11-1.43,p<0.001)。
- 按治疗分析中,持续低剂量喹硫平与主要心血管不良事件(aHR=1.52,95%CI:1.35-1.70,p<0.001)、非致死性缺血性卒中(aHR=1.37,95%CI:1.13-1.68,p=0.002)和心血管死亡(aHR=1.90,95%CI:1.64-2.19,p<0.001)风险升高相关。
- 主要心血管不良事件风险在女性(aHR=1.28,p=0.02)和起始年龄≥65岁者(aHR=1.24,p<0.001)中更高。
- 与SSRIs相比,低剂量喹硫平与主要心血管不良事件(aHR=1.42,p<0.001)、非致死性缺血性卒中(aHR=1.27,p=0.0028)和心血管死亡(aHR=1.72,p<0.001)风险升高相关。
关键数值与推荐
- 主要结局为主要心血管不良事件,定义为非致死性心肌梗死或缺血性卒中或心血管原因死亡。
- 低剂量喹硫平相比Z类药物:意向治疗分析主要心血管不良事件aHR=1.13(95%CI:1.02-1.24),心血管死亡aHR=1.26(95%CI:1.11-1.43)。
- 按治疗分析:主要心血管不良事件aHR=1.52(95%CI:1.35-1.70),非致死性缺血性卒中aHR=1.37(95%CI:1.13-1.68),心血管死亡aHR=1.90(95%CI:1.64-2.19)。
- 相比SSRIs:主要心血管不良事件aHR=1.42,非致死性缺血性卒中aHR=1.27,心血管死亡aHR=1.72。
临床怎么用
- 应避免超说明书使用低剂量喹硫平用于镇静或催眠目的。
- 对女性和≥65岁患者使用低剂量喹硫平时应特别评估心血管风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
At standard doses used for schizophrenia or bipolar disorder, quetiapine has been associated with weight gain and increased levels of triglycerides, to-tal cholesterol and low-density lipoprotein (LDL) cholesterol, which are risk factors for cardiovascular morbidity and mortality. However, this drug is also commonly used off-label at low doses for anxiolytic or hypnotic purposes, and its cardiovascular safety at these doses is unknown. We aimed to assess the risk of major adverse cardiovascular events with use of low-dose quetiapine compared to use of Z-drug hypnotics in a nationwide, active comparator-controlled cohort study. The cohort included new users of either drugs in Denmark from 2003 to 2017, aged 18-85 years, without history of ischemic stroke, myocardial infarction, cancer, and severe mental illness. The main outcome was the occurrence of major adverse cardiovascular events, defined as non-fatal myocardial infarction or ischemic stroke, or death from cardiovascular causes. Selective serotonin reuptake inhibitors (SSRIs) were used as an alternative comparator in sensitivity analyses. Altogether, we compared 60,566 low-dose quetiapine users with 454,567 Z-drug users, followed for 890,198 person-years in intent-to-treat analysis, and 330,334 person-years in as-treated analysis. In intention-to-treat analysis, low-dose quetiapine was associated with an increased risk of major adverse cardiovascular events (adjusted hazard ratio, aHR=1.13, 95% CI: 1.02-1.24, p=0.014) and cardiovascular death (aHR=1.26, 95% CI: 1.11-1.43, p<0.001). In as-treated analysis, continuous low-dose quetiapine use was associated with increased risk of major adverse cardiovascular events (aHR=1.52, 95% CI: 1.35-1.70, p<0.001), non-fatal ischemic stroke (aHR=1.37, 95% CI: 1.13-1.68, p=0.002) and cardiovascular death (aHR=1.90, 95% CI: 1.64-2.19, p<0.001). The risk of major adverse cardiovascular events was greater in women (aHR=1.28, p=0.02) and those aged ≥65 years at initiation (aHR=1.24, p<0.001). Compared to SSRIs, low-dose quetiapine use was associated with an increased risk of major adverse cardiovascular events (aHR=1.42, p<0.001), non-fatal ischemic stroke (aHR=1.27, p=0.0028) and cardiovascular death (aHR=1.72, p<0.001). So, we conclude that the use of low-dose quetiapine is associated with an increased risk of major adverse cardiovascular events, especially in women and the elderly. On the basis of these findings, we suggest that use of off-label low-dose quetiapine for sedative or hypnotic purposes should be discouraged.
引用
- Højlund M, Andersen K, Ernst MT, et al. Use of low-dose quetiapine increases the risk of major adverse cardiovascular events: results from a nationwide active comparator-controlled cohort study. World Psychiatry. 2022. PMID: 36073694. doi:10.1002/wps.21010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。